Cost-effectiveness of ceritinib in previously untreated ALK-positive advanced non-small cell lung cancer in Hong Kong

被引：0
|
作者：
Loong, H. H. [1 ]
Wong, C. K. H. [2 ]
Leung, L. K. S. [3 ]
Chan, C. P. K. [4 ]
Chang, A. [5 ]
Gibbs, M. [6 ]
机构：
[1] Chinese Univ Hong Kong, Dept Clin Oncol, Hong Kong, Peoples R China
[2] Univ Hong Kong, Dept Family Med & Primary Care, Hong Kong, Peoples R China
[3] Prince Wales Hosp, Dept Clin Oncol, Hong Kong, Peoples R China
[4] Novartis Oncol Hong Kong, Med Affairs, Hong Kong, Peoples R China
[5] Novartis Oncol Hong Kong, Market Access, Hong Kong, Peoples R China
[6] Novartis Oncol, Dubai, U Arab Emirates
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
527P
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Clinical observation of crizotinib in the treatment of ALK-positive advanced non-small cell lung cancer
    Deng, Huiyan
    Li, Bin
    Li, Lina
    Peng, Jingcui
    Lv, Tongshuai
    Liu, Yueping
    Ding, Cuimin
    PATHOLOGY RESEARCH AND PRACTICE, 2019, 215 (12)
  • [32] Post-crizotinib management of effective ceritinib therapy in a patient with ALK-positive non-small cell lung cancer
    Won, Brian
    Mambetsariev, Isa
    Salgia, Ravi
    BMC CANCER, 2016, 16
  • [33] COST-EFFECTIVENESS ANALYSIS OF NIVOLUMAB COMPARED TO PEMBROLIZUMAB IN PREVIOUSLY UNTREATED LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER PATIENTS
    Huang, Y.
    Wang, Y.
    Diaby, K.
    VALUE IN HEALTH, 2022, 25 (07) : S414 - S414
  • [34] Post-crizotinib management of effective ceritinib therapy in a patient with ALK-positive non-small cell lung cancer
    Brian Won
    Isa Mambetsariev
    Ravi Salgia
    BMC Cancer, 16
  • [35] COST-EFFECTIVENESS ANALYSIS OF ALECTINIB VERSUS CRIZOTINIB IN FIRST LINE ALK-POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER IN THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM PERSPECTIVE
    Stefani, S. D.
    Santos, M.
    Kashiura, D.
    Leme-Souza, R.
    Fahham, L.
    VALUE IN HEALTH, 2019, 22 : S478 - S479
  • [36] Alectinib for advanced ALK-positive non-small-cell lung cancer
    Ly, Ashley C.
    Olin, Jacqueline L.
    Smith, Morgan B.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2018, 75 (08) : 515 - 522
  • [37] Cost-effectiveness analysis of pembrolizumab plus chemotherapy for previously untreated metastatic non-small cell lung cancer in the USA
    Zeng, Xiaohui
    Wan, Xiaomin
    Peng, Liubao
    Peng, Ye
    Ma, Fang
    Liu, Qiao
    Tan, Chongqing
    BMJ OPEN, 2019, 9 (12): : e031019
  • [38] Treatment of brain metastases in ALK-positive non-small cell lung cancer
    Ceddia, Serena
    Codacci-Pisanelli, Giovanni
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2021, 165
  • [39] How I treat ALK-positive non-small cell lung cancer
    McCusker, Michael G.
    Russo, Alessandro
    Scilla, Katherine A.
    Mehra, Ranee
    Rolfo, Christian
    ESMO OPEN, 2019, 4
  • [40] Lorlatinib: an additional option for ALK-positive non-small cell lung cancer?
    Mogenet, Alice
    Tomasini, Pascale
    Greillier, Laurent
    Barlesi, Fabrice
    TRANSLATIONAL LUNG CANCER RESEARCH, 2019, 8 : S383 - S386
12345